Share on LinkedInShare on LinkedIn

ARTICLE · 14 APRIL 2021

Rocket docket pharma patent litigation taking off in Australia and other emerging trends

Corrs Chambers Westgarth
Corrs Chambers Westgarth
Contributor
Corrs Chambers Westgarth

Corrs Chambers Westgarth

Corrs Chambers Westgarth is Australia’s leading independent law firm. We provide exceptional legal...

View firm profile
Explore more from Corrs Chambers Westgarth

Overview of recent pharmaceutical patent dispute and key takeaways.

AustraliaIntellectual Property

The recent interlocutory decision of Justice Beach in Juno Pharmaceuticals Pty Ltd v Celgene Corporation [2021] FCA 236 is a case study of numerous emerging trends in Australian pharmaceutical patent litigation.

First, it shows the Federal Court's increasing willingness to grant expedited trials in pharmaceutical patent cases at the urging of generic and biosimilar companies. Second, it illustrates the Court's reluctance to prevent a patentee from bringing an infringement case even where the product in question has not obtained regulatory approval. Third, it highlights the increasing appetite of generic and biosimilar companies to attack patents for failure to comply with Australia's idiosyncratic and onerous requirement to disclose the 'best method'.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

    Lawyers Weekly Law firm of the year 2021                  
Employer of Choice for Gender Equality (WGEA)

See more popular content from